Scientific deep-dive

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap

Eructation runs under 1% on placebo against 7% on Wegovy: a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·3 citations

Nausea gets the warnings. Burping does not, and it has the widest relative gap in the entire adverse-reactions table: under 1% on placebo against 7% on Wegovy.[1] That is a sevenfold difference. Nausea, the effect everyone is told about, is under threefold. If you started one of these and found yourself burping in a way you never did before, that is the drug. It is in the label, even if nobody mentioned it.

The numbers, side by side

Upper-gut effects in the adult weight-management trials. Wegovy 2.4 mg against placebo (N=2,116).
EffectPlaceboWegovyRelative gap
Eructation (burping)<1%7%More than sevenfold
Dyspepsia (indigestion)3%9%Threefold
Abdominal distension (bloating)5%7%Modest
Flatulence4%6%Modest
Gastroesophageal reflux3%5%Modest

Reflux needs separating from the rest. At 5% against 3% it is a real but modest increase, far smaller than the burping figure and smaller than many people expect given how much is written about it. For the questions people ask about heartburn in particular, see our reflux and GERD Q&A.

Why it happens: the usual explanation, and its limits

The labels say these drugs delay stomach emptying, and the usual explanation runs from there: food that stays in the stomach longer has more time to produce gas, and puts more pressure below the valve that is supposed to keep stomach contents down. It is a plausible account, not a proven one. The authors of the pooled STEP analysis describe the cause of the stomach side effects as uncertain, note that the longer-acting drugs do not appear to delay emptying much, and point to a 20-week study of semaglutide 2.4 mg that found no measurable delay.[3]

The sulfurous smell many people describe is real enough, but no study has measured what causes it on these drugs. The common explanation is that food fermenting for longer produces sulfur-containing gases that the burping brings up. It is unpleasant, and on its own it is not one of the warning signs the labels list. Other odor changes, in urine, breath and sweat, are covered in smell changes and body odor on a GLP-1.

The likeliest common thread in that table is food moving through more slowly, though for the weekly drugs that has not been proven.

The dose question, which Zepbound's label answers

Wegovy’s table gives one dose against placebo. Zepbound’s is stratified across 5, 10 and 15 mg, which lets you see whether these effects climb with dose.[2] Mostly, they do not.

Zepbound, by dose. Placebo / 5 mg / 10 mg / 15 mg.
EffectPlacebo5 mg10 mg15 mg
Eructation1%4%5%5%
Gastroesophageal reflux2%4%4%5%
Dyspepsia4%9%9%10%

Each of these roughly doubles or triples from placebo to the lowest dose and then flattens. That is a different pattern from fatigue, which keeps climbing with dose. In practice, the burping you get at 5 mg is roughly the burping you get at 15, so if you can tolerate it early, escalation is unlikely to make this particular problem much worse.

What actually helps

No trial has tested remedies for this, so what follows rests on the mechanism and is modest.

  • Smaller meals, eaten more slowly. A stomach that empties slowly copes badly with volume, and swallowed air makes burping worse.
  • Carbonated drinks add gas to a system already holding it. Cutting them is an easy first change to try.
  • Fatty and very large meals sit longest. They also drive reflux independently. So does a lot of coffee; see coffee and caffeine on a GLP-1.
  • Do not lie down after eating, which is standard reflux advice and matters more when the stomach is emptying slowly.
Reflux to raise with a clinician, not manage alone. Persistent heartburn, pain on swallowing, food sticking, vomiting that will not settle, or black stools are not this. Long-running untreated reflux damages the esophagus, and a drug that slows gastric emptying is a reason to take it more seriously. Mention it before any procedure with sedation, too (see holding a GLP-1 before endoscopy). Stomach pain, as opposed to burning, is a separate question, and GLP-1 stomach pain: what is expected and what is a warning sign sets out the patterns the labels single out.

For the effects further down the same system, our constipation guide covers what the labels report and what the evidence supports, and how long side effects last covers the escalation-week pattern most of them follow. Whether a low-FODMAP diet helps with gas and bloating on these drugs is untested; what it does in IBS is set out there.

Frequently Asked Questions

The usual explanation is that the drug slows the stomach, so food sits longer and produces more gas, although that has not been proven for the weekly drugs. The label puts eructation at under 1% on placebo against 7% on Wegovy. That sevenfold difference is the widest relative gap in the whole adverse-reactions table.
No study has measured it on these drugs. The usual explanation is that food staying longer in the stomach produces sulfur-containing gases, which burping brings up. On its own it is not one of the warning signs the labels list; stomach pain that is severe or will not go away is, and is covered in our guide to GLP-1 stomach pain.
Modestly. The Wegovy label reports gastroesophageal reflux in 5% against 3% on placebo, and Zepbound's dose-stratified table runs 2% on placebo against 4–5% across its doses. The increase is real, but much smaller than the burping figure and smaller than many people expect.
Probably not much. Zepbound's table shows these effects roughly doubling or tripling from placebo to the lowest dose and then flattening: eructation runs 4%, 5% and 5% across 5, 10 and 15 mg. That differs from fatigue, which keeps climbing.
Persistent heartburn, pain on swallowing, a sense of food sticking, vomiting that will not settle, or black stools. Long-running untreated reflux damages the esophagus. Flag it, too, before any procedure involving sedation.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: eructation, dyspepsia, abdominal distension, flatulence and gastroesophageal reflux disease (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. 2022. PMID: 34514682.

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

GLP-1 Allergic Reactions and Anaphylaxis: What the Labels and Cases Show

True allergy to semaglutide or tirzepatide is real but rare: about 3.6 anaphylaxis cases per 10,000 person-years on semaglutide. What each label says, how antibodies and inactive ingredients fit in, whether another GLP-1 is safe after a reaction, and when to call 911.

11 min read

Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter

Every GLP-1 raises resting heart rate by a few beats a minute, but only Wegovy and Saxenda warn about it. What the labels show, why it happens, whether it matters, and the palpitations that point elsewhere.

9 min read

Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say

No GLP-1 label names an antidepressant as an interaction, and people on antidepressants lost as much weight on semaglutide as everyone else. The real overlaps: stacked nausea, slowed absorption of tablets, and two bupropion rules.

11 min read

Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign

Stomach pain on Ozempic, Wegovy, Mounjaro or Zepbound is usually mild and comes with the dose increases. The labels describe the patterns that are not ordinary, and little of the usual advice has been tested.

8 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.1

Collective

From $69/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →